Polyrizon (NASDAQ:PLRZ) Trading 1.7% Higher – Still a Buy?

Shares of Polyrizon Ltd. (NASDAQ:PLRZ) traded up 1.7% during mid-day trading on Tuesday . The company traded as high as $13.92 and last traded at $13.49. 18,732 shares changed hands during mid-day trading, a decline of 48% from the average daily volume of 35,779 shares. The stock had previously closed at $13.26.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on PLRZ shares. Wall Street Zen upgraded shares of Polyrizon from a “sell” rating to a “hold” rating in a report on Sunday, June 7th. Weiss Ratings upgraded Polyrizon from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 13th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Polyrizon Price Performance

The stock’s 50 day simple moving average is $13.54 and its 200-day simple moving average is $13.60.

Institutional Investors Weigh In On Polyrizon

An institutional investor recently bought a new position in Polyrizon stock. Jane Street Group LLC bought a new position in shares of Polyrizon Ltd. (NASDAQ:PLRZ) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 14,032 shares of the company’s stock, valued at approximately $119,000. Jane Street Group LLC owned about 1.35% of Polyrizon at the end of the most recent reporting period.

Polyrizon Company Profile

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.